General Myelodysplastic Syndrome

Vidaza® Approved for High-risk MDS (08-22-2008)

Vidaza® Approved for High-risk MDS The US Food and Drug Administration (FDA) has approved Vidaza® (azacitadine) for the treatment of high-risk myelodysplastic syndromes. Vidaza is already approved for MDS that is categorized into all five French American... Continue Reading

Supportive Care and Hematologic Malignancies (01-21-2008)

Supportive Care and Hematologic Malignancies: A Report from the 2007 American Society of Hematology (ASH) Meeting Introduction At the 2007 meeting of the American Society of Hematology (ASH) the most interesting supportive care studies involved second... Continue Reading

Updates in the Management of Myelodysplastic Syndromes (01-21-2008)

Updates in the Management of Myelodysplastic Syndromes: A Report from the 2007 American Society of Hematology (ASH) Meeting IntroductionCytopenias – The Double-Edged SwordHypomethylating Agents – Living the Good LifeImmunomodulatory Agents Extend... Continue Reading

« Previous Page